2 results
Approved WMOCompleted
To determine the Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 of CriPec® docetaxel monotherapy in subjects with ovarian cancer who are resistant to prior platinum-based therapy.
Approved WMORecruiting
The primary objective is to investigate the efficacy of VR, complementary to standard care, in reducing intensity of pain in SCD patients hospitalized with VOC compared to the efficacy of another distraction method (tablet use) next to standard care…